Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective

Objective: To evaluate the effectiveness and safety of totally thoracoscopic ablation (TTA) in patients with left ventricular (LV) dysfunction for treatment of atrial fibrillation (AF) refractory to antiarrhythmic drug (AAD) therapy. Methods: Between January 2012 and December 2018, 31 patients under...

Full description

Saved in:
Bibliographic Details
Main Authors: Hye Ree Kim, MD, Dong-Seop Jeong, MD, PhD, Hee-Jin Kwon, MD, Seung-Jung Park, MD, PhD, Kyoung-Min Park, MD, PhD, June Soo Kim, MD, PhD, Young Keun On, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:JTCVS Techniques
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666250721002984
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849405464204279808
author Hye Ree Kim, MD
Dong-Seop Jeong, MD, PhD
Hee-Jin Kwon, MD
Seung-Jung Park, MD, PhD
Kyoung-Min Park, MD, PhD
June Soo Kim, MD, PhD
Young Keun On, MD, PhD
author_facet Hye Ree Kim, MD
Dong-Seop Jeong, MD, PhD
Hee-Jin Kwon, MD
Seung-Jung Park, MD, PhD
Kyoung-Min Park, MD, PhD
June Soo Kim, MD, PhD
Young Keun On, MD, PhD
author_sort Hye Ree Kim, MD
collection DOAJ
description Objective: To evaluate the effectiveness and safety of totally thoracoscopic ablation (TTA) in patients with left ventricular (LV) dysfunction for treatment of atrial fibrillation (AF) refractory to antiarrhythmic drug (AAD) therapy. Methods: Between January 2012 and December 2018, 31 patients underwent TTA with drug-refractory AF and preoperative left ventricular ejection fraction (LVEF) <50% were included. Of the 31 patients, 8 received additional catheter ablation with an electrophysiologic study within 3 months after TTA. The rhythm outcome was obtained by 12-lead electrocardiography or 24-hour Holter monitoring. Results: The patient cohort had a mean age of 54.9 ± 9.0 years and consisted of 51.6% with persistent AF (n = 16), 45.2% with long-standing persistent AF (n = 14), and 3.2% with paroxysmal AF (n = 1). No patients died during the follow-up period. Compared with baseline, mean postoperative LVEF at 3 months (interquartile range [IQR], 2-6 months) increased significantly (from 39.7 ± 6.1% to 53.6 ± 9.3%; P < .001). At 25 months (IQR, 14-45 months), LVEF was sustained or further improved (from 39.7 ± 6.1% to 58.1 ± 7.5%; P < .001). The rate of sinus rhythm state was 93.5% (29 of 31), and freedom from arrhythmias off AADs after the final procedure was 61.3% (19 of 31) at a median follow-up of 32 months (IQR, 24-54 months). Conclusions: TTA is a safe and effective procedure that improves LV function and restores sinus rhythm in AF patients with LV dysfunction.
format Article
id doaj-art-41efe1ffb641460aa11ff90dbf5c128e
institution Kabale University
issn 2666-2507
language English
publishDate 2021-08-01
publisher Elsevier
record_format Article
series JTCVS Techniques
spelling doaj-art-41efe1ffb641460aa11ff90dbf5c128e2025-08-20T03:36:41ZengElsevierJTCVS Techniques2666-25072021-08-018606610.1016/j.xjtc.2021.04.006Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspectiveHye Ree Kim, MD0Dong-Seop Jeong, MD, PhD1Hee-Jin Kwon, MD2Seung-Jung Park, MD, PhD3Kyoung-Min Park, MD, PhD4June Soo Kim, MD, PhD5Young Keun On, MD, PhD6Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular and Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular and Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular and Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular and Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular and Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular and Stroke Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Address for reprints: Young Keun On, MD, PhD, Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Heart, Vascular, and Stroke Institute, Sungkyunkwan University School of Medicine, 81 Irwin-ro, Gangnam-gu, Seoul 06351, Republic of Korea.Objective: To evaluate the effectiveness and safety of totally thoracoscopic ablation (TTA) in patients with left ventricular (LV) dysfunction for treatment of atrial fibrillation (AF) refractory to antiarrhythmic drug (AAD) therapy. Methods: Between January 2012 and December 2018, 31 patients underwent TTA with drug-refractory AF and preoperative left ventricular ejection fraction (LVEF) <50% were included. Of the 31 patients, 8 received additional catheter ablation with an electrophysiologic study within 3 months after TTA. The rhythm outcome was obtained by 12-lead electrocardiography or 24-hour Holter monitoring. Results: The patient cohort had a mean age of 54.9 ± 9.0 years and consisted of 51.6% with persistent AF (n = 16), 45.2% with long-standing persistent AF (n = 14), and 3.2% with paroxysmal AF (n = 1). No patients died during the follow-up period. Compared with baseline, mean postoperative LVEF at 3 months (interquartile range [IQR], 2-6 months) increased significantly (from 39.7 ± 6.1% to 53.6 ± 9.3%; P < .001). At 25 months (IQR, 14-45 months), LVEF was sustained or further improved (from 39.7 ± 6.1% to 58.1 ± 7.5%; P < .001). The rate of sinus rhythm state was 93.5% (29 of 31), and freedom from arrhythmias off AADs after the final procedure was 61.3% (19 of 31) at a median follow-up of 32 months (IQR, 24-54 months). Conclusions: TTA is a safe and effective procedure that improves LV function and restores sinus rhythm in AF patients with LV dysfunction.http://www.sciencedirect.com/science/article/pii/S2666250721002984totally thoracoscopic ablationsurgical ablationatrial fibrillationheart failureleft ventricular dysfunctioncatheter ablation
spellingShingle Hye Ree Kim, MD
Dong-Seop Jeong, MD, PhD
Hee-Jin Kwon, MD
Seung-Jung Park, MD, PhD
Kyoung-Min Park, MD, PhD
June Soo Kim, MD, PhD
Young Keun On, MD, PhD
Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective
JTCVS Techniques
totally thoracoscopic ablation
surgical ablation
atrial fibrillation
heart failure
left ventricular dysfunction
catheter ablation
title Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective
title_full Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective
title_fullStr Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective
title_full_unstemmed Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective
title_short Total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctionCentral MessagePerspective
title_sort total thoracoscopic ablation in patients with atrial fibrillation and left ventricular dysfunctioncentral messageperspective
topic totally thoracoscopic ablation
surgical ablation
atrial fibrillation
heart failure
left ventricular dysfunction
catheter ablation
url http://www.sciencedirect.com/science/article/pii/S2666250721002984
work_keys_str_mv AT hyereekimmd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective
AT dongseopjeongmdphd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective
AT heejinkwonmd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective
AT seungjungparkmdphd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective
AT kyoungminparkmdphd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective
AT junesookimmdphd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective
AT youngkeunonmdphd totalthoracoscopicablationinpatientswithatrialfibrillationandleftventriculardysfunctioncentralmessageperspective